These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 25378205)

  • 1. Pharmacokinetics and pharmacodynamics following intravenous administration of recombinant human hepatocyte growth factor in rats with renal injury.
    Adachi E; Hirose-Sugiura T; Kato Y; Ikebuchi F; Yamashita A; Abe T; Fukuta K; Adachi K; Matsumoto K
    Pharmacology; 2014; 94(3-4):190-7. PubMed ID: 25378205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic modeling of hepatocyte growth factor in experimental animals and humans.
    Sugiura T; Takahashi S; Sano K; Abe T; Fukuta K; Adachi K; Nakamura T; Matsumoto K; Nakamichi N; Kato Y
    J Pharm Sci; 2013 Jan; 102(1):237-49. PubMed ID: 23047829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of tubular cell proliferation by neutralizing endogenous HGF leads to renal hypoxia and bone marrow-derived cell engraftment in acute renal failure.
    Ohnishi H; Mizuno S; Nakamura T
    Am J Physiol Renal Physiol; 2008 Feb; 294(2):F326-35. PubMed ID: 18032545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatocyte growth factor modification promotes the amelioration effects of human umbilical cord mesenchymal stem cells on rat acute kidney injury.
    Chen Y; Qian H; Zhu W; Zhang X; Yan Y; Ye S; Peng X; Li W; Xu W
    Stem Cells Dev; 2011 Jan; 20(1):103-13. PubMed ID: 20446811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatocyte growth factor may function as a renotropic factor for regeneration in rats with acute renal injury.
    Igawa T; Matsumoto K; Kanda S; Saito Y; Nakamura T
    Am J Physiol; 1993 Jul; 265(1 Pt 2):F61-9. PubMed ID: 8342615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocyte growth factor protects functional and histological disorders of HgCl(2)-induced acute renal failure mice.
    Yamasaki N; Nagano T; Mori-Kudo I; Tsuchida A; Kawamura T; Seki H; Taiji M; Noguchi H
    Nephron; 2002 Feb; 90(2):195-205. PubMed ID: 11818705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatocyte growth factor ameliorates renal interstitial inflammation in rat remnant kidney by modulating tubular expression of macrophage chemoattractant protein-1 and RANTES.
    Gong R; Rifai A; Tolbert EM; Biswas P; Centracchio JN; Dworkin LD
    J Am Soc Nephrol; 2004 Nov; 15(11):2868-81. PubMed ID: 15504940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endogenous hepatocyte growth factor attenuates inflammatory response in glycerol-induced acute kidney injury.
    Homsi E; Janino P; Amano M; Saraiva Camara NO
    Am J Nephrol; 2009; 29(4):283-91. PubMed ID: 18824844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attenuation of glycerol-induced acute kidney injury by previous partial hepatectomy: role of hepatocyte growth factor/c-met axis in tubular protection.
    Homsi E; Janino P; Biswas SK; Mizuno S; Nakamura T; Lopes de Faria JB
    Nephron Exp Nephrol; 2007; 107(3):e95-106. PubMed ID: 17940345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatocyte growth factor prevents acute renal failure and accelerates renal regeneration in mice.
    Kawaida K; Matsumoto K; Shimazu H; Nakamura T
    Proc Natl Acad Sci U S A; 1994 May; 91(10):4357-61. PubMed ID: 8183913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and safety of human recombinant hepatocyte growth factor administered to vocal folds.
    Mizuta M; Hirano S; Kishimoto Y; Hiwatashi N; Tateya I; Kanemaru S; Nakamura T; Ito J
    Laryngoscope; 2014 Sep; 124(9):2131-5. PubMed ID: 24668496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant human erythropoietin reduces rhabdomyolysis-induced acute renal failure in rats.
    Yang FL; Subeq YM; Chiu YH; Lee RP; Lee CJ; Hsu BG
    Injury; 2012 Mar; 43(3):367-73. PubMed ID: 22209169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms underlying the renoprotective effect of GABA against ischemia/reperfusion-induced renal injury in rats.
    Kobuchi S; Tanaka R; Shintani T; Suzuki R; Tsutsui H; Ohkita M; Ayajiki K; Matsumura Y
    J Pharmacol Exp Ther; 2011 Sep; 338(3):767-74. PubMed ID: 21632868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repeated intravenous injection of recombinant human hepatocyte growth factor ameliorates liver cirrhosis but causes albuminuria in rats.
    Kusumoto K; Ido A; Moriuchi A; Katsura T; Kim I; Takahama Y; Numata M; Kodama M; Hasuike S; Nagata K; Uto H; Inui K; Tsubouchi H
    Int J Mol Med; 2006 Mar; 17(3):503-9. PubMed ID: 16465399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ameliorative effect of hepatocyte growth factor on glycerol-induced acute renal failure with acute tubular necrosis.
    Nagano T; Mori-Kudo I; Tsuchida A; Kawamura T; Taiji M; Noguchi H
    Nephron; 2002 Aug; 91(4):730-8. PubMed ID: 12138279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human hepatocyte growth factor protects the liver against hepatic ischemia and reperfusion injury in rats.
    Sakakura Y; Kaibori M; Oda M; Okumura T; Kwon AH; Kamiyama Y
    J Surg Res; 2000 Aug; 92(2):261-6. PubMed ID: 10896832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocyte growth factor in glycerol-induced acute renal failure.
    Goto T; Sugimura K; Harimoto K; Kasai S; Kim T; Kishimoto T
    Nephron; 1997; 77(4):440-4. PubMed ID: 9434067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocyte growth factor-induced amelioration in renal interstitial fibrosis is associated with reduced expression of alpha-smooth muscle actin and transforming growth factor-beta1.
    Wang HY; Wang YJ; Cui MJ; Gu CM; Yang LZ; Zhao Y; Chen Y; Zhao D; Li TS; Chi BR
    Indian J Biochem Biophys; 2011 Oct; 48(5):308-15. PubMed ID: 22165288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and pharmacokinetics of recombinant human hepatocyte growth factor (rh-HGF) in patients with fulminant hepatitis: a phase I/II clinical trial, following preclinical studies to ensure safety.
    Ido A; Moriuchi A; Numata M; Murayama T; Teramukai S; Marusawa H; Yamaji N; Setoyama H; Kim ID; Chiba T; Higuchi S; Yokode M; Fukushima M; Shimizu A; Tsubouchi H
    J Transl Med; 2011 May; 9():55. PubMed ID: 21548996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective effects of peroxisome proliferator-activated receptor gamma ligand on apoptosis and hepatocyte growth factor induction in renal ischemia-reperfusion injury.
    Doi S; Masaki T; Arakawa T; Takahashi S; Kawai T; Nakashima A; Naito T; Kohno N; Yorioka N
    Transplantation; 2007 Jul; 84(2):207-13. PubMed ID: 17667812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.